Gao D, Vahdat LT, Wong S, et al. Microenvironmental regulation of epithelial- mesenchymal transitions in cancer[J].Cancer Res, 2012,72(19):4883-4889.
[2]
Falany CN, He D, Dumas N, et al. Human cytosolic sulfotransferase 2B1: isoform expression, tissue specificity and subcellular localization [J]. J Steroid Biochem Mol Biol, 2006, 102(1-5):214-221.
[3]
Li X, Pandak WM, Erickson SK, et al. Biosynthesis of the regulatory oxysterol, 5-cholesten-3beta,25-diol 3-sulfate, in hepatocytes [J]. J Lipid Res, 2007, 48(12):2587-2596.
[4]
Bai Q, Xu L, Kakiyama G, et al. Sulfation of 25-hydroxycholesterol by SULT2B1b decreases cellular lipids via the LXR/SREBP-1c signaling pathway in human aortic endothelial cells [J]. Atherosclerosis, 2011, 214(2): 350-356.
[5]
Lo SG, Celli N, Caboni M, et al. Down-regulation of the LXR transcriptome provides the requisite cholesterol levels to proliferating hepatocytes [J]. Hepatology, 2010, 51(4):1334-1344.
[6]
Zhang X, Bai Q, Xu L, et al. Cytosolic sulfotransferase 2B1b promotes hepatocyte proliferation gene expression in vivo and in vitro [J]. Am J Physiol Gastrointest Liver Physiol, 2012, 303(3):344-355.
[7]
Zhang X, Bai Q, Kakiyama G, et al. Cholesterol metabolite, 5-cholesten- 3beta- 25-diol-3-sulfate, promotes hepatic proliferation in mice [J]. J Steroid Biochem Mol Biol, 2012,132(3-5):262-270.
[8]
Yang X, Xu Y, Guo F, et al. Hydroxysteroid sulfotransferase SULT2B1b promotes hepatocellular carcinoma cells proliferation in vitro and In Vivo [J]. PLoS One, 2013, 8(4):e60853.
[9]
Fu J, Weise AM, Falany JL, et al. Expression of estrogenicity genes in a lineage cell culture model of human breast cancer progression[J]. Breast Cancer Res Treat, 2010,120(1):35-45.
[10]
He D, Falany CN. Inhibition of SULT2B1b expression alters effects of 3beta-hydroxysteroids on cell proliferation and steroid hormone receptor expression in human LNCaP prostate cancer cells [J]. Prostate, 2007, 67(12): 1318-1329.
[11]
Hevir N, Sinkovec J, Rizner TL. Disturbed expression of phase I and phase II estrogen-metabolizing enzymes in endometrial cancer: lower levels of CYP1B1 and increased expression of S-COMT [J]. Mol Cell Endocrinol, 2011, 331(1): 158-167.
[12]
Hyland PL, Freedman ND, Hu N, et al. Genetic variants in sex hormone metabolic pathway genes and risk of esophageal squamous cell carcinoma [J]. Carcinogenesis, 2013, 34(5):1062-1068.
[13]
Ksiazkiewicz M, Markiewicz A, Zaczek AJ. Epithelial-mesenchymal transition: a hallmark in metastasis formation linking circulating tumor cells and cancer stem cells [J]. Pathobiology, 2012, 79(4):195-208.
[14]
Foroni C, Broggini M, Generali D, et al. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact [J]. Cancer Treat Rev, 2012, 38(6):689-697.
